Clinical Trials Logo
  1. Home
  2. Ovarian Cancer
  3. NCT06238284
  4. Details
NCT06238284 Clinical Trial

HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China

Ovarian Cancer Clinical Trial

Official title:
HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06238284
Other study ID # CQ-HER2-GYN
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 26, 2024
Est. completion date May 31, 2024

Study information
Verified date June 2023
Source Chongqing University Cancer Hospital
Contact Qi Zhou, PH.D
Phone 13708384529
Email qizhou9128@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 300
Est. completion date May 31, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients with primary gynecological malignant tumor confirmed by histopathology - Women aged 18-75 - The expected survival time is greater than 12 weeks - KPS > 60, ECOG score is 0-2 - All subjects voluntarily joined this study with informed consents, and had good compliance of follow-up Exclusion Criteria: - Pregnant and lactating women - Suffering from other malignant tumors in the past 5 years - Patients who are not suitable for this study according to the investigator's judgment

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• no intervention
Since it is a retrospective study, no intervention is needed.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Chongqing University Cancer Hospital

Outcome
Type Measure Description Time frame Safety issue
Primary HER2 status HER2 exprssion level evaluated by pathologists from 2023.07 to 2024.05
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2